Quick Answer
Zentalis Pharmaceuticals, Inc. reported Operating Income of -$152.81 million for fiscal year 2025.
Zentalis Pharmaceuticals, Inc. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | -$152.81M | +20.1% |
| 2024 | -$191.19M | +36.2% |
| 2023 | -$299.51M | -31.8% |
| 2022 | -$227.29M | -5.0% |
| 2021 | -$216.54M | -82.3% |
| 2020 | -$118.79M | -153.6% |
| 2019 | -$46.84M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$33.73M | +34.4% | +6.4% |
| June 30, 2025 | -$36.06M | +44.7% | +21.0% |
| March 31, 2025 | -$45.62M | -84.2% | +11.3% |
| September 30, 2024 | -$51.43M | +18.0% | +21.1% |
| June 30, 2024 | -$65.15M | +37.3% | -163.1% |
| March 31, 2024 | -$24.77M | +61.9% | +60.5% |
| September 30, 2023 | -$62.72M | -15.7% | +39.6% |
| June 30, 2023 | -$103.92M | -63.7% | -60.0% |
- Zentalis Pharmaceuticals, Inc. showed an increase of +20.1% in Operating Income compared to the prior fiscal year.
- Over the 2019–2025 period, Zentalis Pharmaceuticals, Inc.’s operating income has declined by 226.2% (from -$46.84 million to -$152.81 million).
- The most recent figure is from Zentalis Pharmaceuticals, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: